Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in t ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. A number ...

After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...

EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical ...

NEW YORK(Reuters) - Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new directors to prioritize the development of the company's ...